James Black Foundation Limited

Iain Mair McDonald

Sarkis Barret Kalindjian

Caroline M Low

Michael John Pether

Matthew John Tozer

David John Dunstone

Ildiko Maria Buck

Nigel Paul Shankley

Katherine Isobel Steel

Jonathan Michael Davies

Ian Duncan Linney

Elaine Anne Harper

Robert A Hull

Martin Lyn Hudson

Caroline Minli Rachel Low

Katherine Isobel Mary Steel

Gillian Fairfull Watt

Howard B Broughton

Paul Wright

James Black

Sonia Patricia Roberts

Tracey Cooke

Jeremy Gilbert Vinter

John Spencer

Martin Keith Walker

Elliot James Lilley

David Andrew Sykes

Eric Peter Griffin

Laurence Wright

John David Gaffen

Michael J Bodkin

Robert Antony David Hull

Compounds of the formula (I) or (II) and their pharmaceutically acceptable salts are ligands at gastrin and/or chole-cystokinin receptors n is from 1 to 4; Ris Cto Chydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; Z is &#x2014;(NR)&#x2014;CO&#x2014;(NR)-(wherein a is 0 or 1, b is 0 or 1, and Rand Rare independently selected from H, Me, Et, Pr, Bn), &#x2014;CO&#x2014;NR&#x2014;CH&#x2014;CO&#x2014;NR&#x2014;, &#x2014;CO&#x2014;O&#x2014;, &#x2014;CH&#x2014;CH&#x2014;, &#x2014;CH&#x2550;CH&#x2014;, CH&#x2014;NR&#x2014; or a bond; Q is RV, or(a) wherein Ris &#x2014;CH&#x2014;; &#x2014;CH&#x2014;; or(b) Rand R, together with the nitrogen atom to which Ris attached, form a piperidine or pyrrolidine ring which is substituted by V; V is &#x2014;CO&#x2014;NH&#x2014;SO-Ph, &#x2014;SO&#x2014;NH&#x2014;CO-Ph, CHOH, or a group of the formula &#x2014;RU, (wherein U is &#x2014;COOH, tetrazolyl, &#x2014;CONHOH&#x2014; or &#x2014;SOH; and Ris a bond; Cto Chydrocarbylene, optionally substituted by hydroxy, amino or acetamino; &#x2014;O&#x2014;(Cto Calkylene)-; &#x2014;SONR&#x2014;CHR&#x2014;; &#x2014;CO&#x2014;NR&#x2014;CHR&#x2014;, Rand Rbeing independently selected from H and methyl; or &#x2014;NH&#x2014;(CO)&#x2014;CH&#x2014;, c being 0 or 1); m is 1 or 2; q is from 0 to 2, with the proviso that q is 1 or 2 when Z is a bond); Compositions comprising a compound of formula (I) or (II) are also described.

Gastrin and cholecystokinin receptor lignads (iv)

Compounds of formula (I), (IIa) or (IIb) wherein R-R, Z, Q and n are as defined in claimand their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. Compositions comprising a compound of formula (I), (IIa) or (IIb) are also described.

Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands

Gastrin and cholecystokinin receptor ligands

Histamine H.sub.3 receptor ligands

Sulfonamides and sulfamides as H.sub.3 receptor antagonists

Benzodiazonine derivatives binding to cholecystokinin or gastrin

Compounds of formula (Ia), (Ib), or (Ic), wherein A represents a group having two fused rings, or a group of formula (Id), R.sup.1.sub.(m) represents up to 6 substituents, K represents --O--, --S--, --CH.sub.2 --, --N(R.sup.2)-- or --N(COR.sup.2)--, in which R.sup.2 is H or C.sub.1 to C.sub.3 alkyl, W is a carbonyl, sulfonyl or sulfinyl group, provided that at least one of W and X contains carbonyl, Y and Z are as given in the description, and their pharmaceutically acceptable salts are ligands at CCK and/or gastrin receptors. ##STR1##

Gastrin and cck receptor ligands

Amino acid derivatives with anticholecystokinin activity

Gastin and CCK receptor ligands

Bicyclooctane and bicycloheptane derivatives

The compounds of the formula I ##STR1## and their pharmaceutical acceptable salts, which are defined herein, are ligands for cholecystokinin and/or gastrin receptors.

Bicyclo 2,2,2!octane derivatives

Tetrapeptide derivatives and analogues

Derivatives of aspartic acid and glutamic acid having

Growing community of inventors

Paddock Wood, United Kingdom

Iain Mair McDonald